Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

This investor's weighing up a couple of world-class companies for his Stocks and Shares ISA after the US election sparked a sell-off.

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday ...